AMGN enters July having quietly put together its best monthly stretch in some time — up 7.5% over the past month and 4.4% on the week to close at $362.12 — yet the rally has done little to shift Wall Street's firmly neutral posture ahead of Q2 results due August 4.
Options traders are leaning constructively, not defensively. The put/call ratio has dropped to 0.77, sitting roughly 1.2 standard deviations below its 20-day average of 0.82 — a clear shift toward call activity relative to recent norms. The move is notable because it reverses a more hedged pattern that dominated through May and early June, when the PCR was regularly printing above 0.85 and briefly touching 1.00. Borrow conditions remain extremely loose. Availability is at approximately 5,500% — meaning there are roughly 55 shares available to lend for every one currently borrowed — and that figure has widened sharply over the past week. Short interest itself is modest at 2.3% of the free float and has declined nearly 3% on the week, continuing a drift lower from a June 8 peak near 13.2 million shares. Borrowing cost is a negligible 0.52% annualised, up about 40% on the week in percentage-change terms but still well within the loose-borrow range. Taken together, positioning looks constructive rather than pressured: shorts are trimming, availability is ample, and options traders are reaching for upside.
The Street is less enthusiastic. The consensus remains a hold with a mean price target of $354.76 — fractionally below the current price of $362.12, which puts the stock trading through the analyst consensus for the first time in a while. Morgan Stanley has twice lifted its target in recent months, most recently to $340 in mid-June while maintaining Equal-Weight; the move reflects recognition of improving momentum but stops well short of endorsing the current price level. Mizuho also raised its target to $303 in June, again at Neutral. The only clear bull on the recent tape is UBS, which moved its target to $400 in April with a Buy. The bull case centres on portfolio depth — Tezspire's growth trajectory, the biologics franchise, and optionality from the Onyx acquisition — while bears point to patent-cliff risk on legacy drugs and persistent pricing pressure across biopharma. The ORTEX short score has eased to 35.7, in the lower third of its recent range, consistent with fading bearish conviction. The dividend factor scores at the 98th percentile, a useful anchor for long-only holders, while EPS surprise lands near the 27th percentile — the company has not been a consistent beat story.
The earnings history reinforces a pattern of contained reactions. The most recent print in May produced a one-day gain of 2.2% and a five-day gain of 3.6%; the prior quarter's result in late April moved the stock 2.4% lower on the day and stayed there over the following week. Moves have been small in both directions. With Q2 due August 4 and the stock now trading above the analyst consensus, the setup heading into that print is less about whether Amgen can deliver and more about whether the recent re-rating can be justified by numbers that have historically landed close to — but not always ahead of — expectations.
Among peers, BIIB gained 9.6% on the week and INCY was up 8.6%, with ABBV adding 7.2% — suggesting the whole large-cap biotech complex caught a bid, which puts Amgen's 4.4% weekly gain in more modest relative relief. The gap between Amgen's move and the peer group is worth watching as August approaches: if sector momentum stalls before earnings, a stock already trading through consensus has less cushion.
See the live data behind this article on ORTEX.
Open AMGN on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
